PENELOPE: TAR-200 Shows Deeper Tissue Penetration vs Standard Intravesical Therapy
8:50
The SunRISe Trials and TAR-200: Bladder-Sparing Therapies for NMIBC
8:15
Novel intravesical chemotherapy delivery system in NMIBC
8:33
The ABLE-32 Study: Nadofaragene Firadenovec for Intermediate-Risk NMIBC
26:56
Bladder Cancer Immunotherapy: Building on a history of immune response
6:18
New drug delivery systems for bladder cancer
1:03:29
#81 - POURQUOI NOS MODES DE VIE VONT DISPARAITRE ? ARTHUR KELLER
12:17
TAR-200 Monotherapy for NMIBC Durability and Dwell Time
17:18